Diabetes mellitus increases the risk and accelerates the clinical course of atherosclerosis, and is responsible for majority of the deaths and disabilities in type 2 diabetic population.[1] Optimal strategies to prevent the onset or progression of atherosclerosis will improve the clinical outcome of this high-risk population. In the current study, the research team showed that two antidiabetic ...

Diabetes mellitus is associated with accelerated atherosclerosis and increased morbidity and mortality in micro-and macrovascular complications. The metabolic derangements that accompany diabetes can adversely influence platelets and vascular endothelial function, which may contribute to the pathogenesis of diabetic angiopathy. This thesis aimed to examine the effect of acute and postprandial h...

The availability of diabetes drugs with new properties in the last several years has prompted excitement about potential new and unique advantages for diabetes care. That has certainly been the case with the new insulin secretagogues, repaglinide and nateglinide, which have earlier onset and shorter duration of action than the sulfonylureas. The niche that insulin secretagogues occupy brings un...

Numerous oral antidiabetic drugs with different mechanisms of action have been developed to lower glucose and delay the occurrence of serious complications in patients with type 2diabetes [1]. For glycemic control in diabetic patients, monotherapy with an oral antidiabetic agent is not adequate to achieve satisfactory blood glucose control [2]. Thus, combination regimens which include drugs wit...